NCT05386888View on ClinicalTrials.gov

A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

September 9, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
NSCLC, Stage III
Interventions
DRUG

GFH018

Administered as oral

DRUG

Toripalimab

Administered as an IV infusion

DRUG

Paclitaxel

Administered as an IV infusion

DRUG

Carboplatin

Administered as an IV infusion

DRUG

Cisplatin

Administered as an IV infusion

DRUG

Pemetrexed

Administered as an IV infusion

RADIATION

Thoracic Radiation Therapy (TRT)

Thoracic Radiation Therapy (TRT)

DRUG

GFH018

Administered as an IV infusion

Trial Locations (1)

610000

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

Genfleet Therapeutics (Shanghai) Inc.

INDUSTRY